Kai‐Cheng Chang

Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan

Yu‐Chen Su, Jia‐Horung Hung, Kai‐Cheng Chang et al. · JAMA Network Open · 2022 · 51 citations · Full text

Dipeptidyl peptidase‐4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population‐based cohort study

Wen‐Hsuan Hou, Kai‐Cheng Chang, Chung‐Yi Li et al. · British Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan

Shih‐Chieh Shao, Yu‐Chen Su, Edward Chia‐Cheng Lai et al. · Diabetes & Metabolism · 2022 · 37 citations

Hypertension, Diabetes Epidemiology, Ophthalmology +8

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second‐ and third‐line antidiabetic drugs in patients with type 2 diabetes

Huang‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li et al. · British Journal of Clinical Pharmacology · 2017 · 34 citations · Full text

Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation‐wide population‐based study from Taiwan

Huang‐Tz Ou, Kai‐Cheng Chang, Ya‐Ming Liu et al. · Journal of Diabetes · 2016 · 31 citations · Full text